a 002

Varespladib methyl (LY333013), a bioavailable prodrug of Varespladib, is a selective group II secretory phospholipase A2 inhibitor.

GNA002 is a highly potent, specific, and covalent EZH2 (Enhancer of zeste homolog 2) inhibitor with an IC50 of 1.1 μM.

ATX-002 is a property-tunable lipid for RNA drug delivery.

The S-enantiomer of BET-BAY 002, referred to as BET-BAY 002 S enantiomer, is a potent inhibitor of BET (Bromodomain and Extra-Terminal motif proteins).

BET-BAY 002 is an effective BET bromodomain inhibitor demonstrating efficacy in vivo and in vitro against multiple myeloma and leukaemia models.

BSJ-05-002 serves as a FAK PROTAC.

SPP-002 is a sulfate ester analogue that acts as a potential Sialyltransferase (ST) inhibitor. It selectively inhibits N-glycan sialylation with at least an order of magnitude greater potency compared to the unmodified parent lithocholic acid (LCA). By inhibiting the integrin/FAK/paxillin signaling pathway, SPP-002 reduces tumor cell migration and invasion. It is applicable in research on tumor metastasis.

WZH-17-002 is an ALKPROTAC degrader based on WZH-15-125, with a DC50 of 25 nM. This compound enhances the efficacy against ALK mutations that confer resistance to Lorlatinib. Moreover, WZH-17-002 significantly reduces resistance in ALK fusion non-small cell lung cancer (NSCLC) and inhibits tumor growth in EML4-ALK G1202R/L1196M xenograft mouse models.

I3IN-002 is a small molecule inhibitor targeting the RNA-binding protein IGF2BP3, with an IC50 value of approximately 2 μM in SEM cells. It disrupts the interaction with m6A-modified mRNA, destabilizing target genes (such as CDK6, MYC, and BCL2), thereby inhibiting the growth of leukemia cells, inducing cell cycle arrest, and promoting apoptosis. I3IN-002 shows potential for research in B-cell acute lymphoblastic leukemia.

MolPort-002-705-878 is a highly selective inhibitor of FMS-like tyrosine kinase 3 (FLT3), with a binding affinity of -11.33 kcal/mol. It effectively suppresses the proliferation of FLT3-mutant acute myeloid leukemia (AML) cells and holds potential for research into FLT3-mutant AML.

ABT-002 is a molecular glue degrader that targets GSPT1 and NEK7, and it shows promise for research in hepatocellular carcinoma (HCC).

EYE-002 is an RPE65 inhibitor with an IC50 of 69 nM. It enhances the recovery of dark-adapted electroretinogram (ERG) a-/b-wave amplitudes in mice. EYE-002 regulates the visual cycle in mice by reducing 11-cisretinal (11cRAL) synthesis and increasing all-trans-retinyl esters (atREs). It offers protective effects against light-induced retinal damage in mice. EYE-002 is valuable for research on retinal disorders related to the visual cycle, such as Stargardt disease type 1 (STGD1).

ZLc-002 is a selective small-molecule inhibitor of nNOS-Capon coupling. ZLc-002 suppresses inflammatory nociception and chemotherapy-induced neuropathic pain. ZLc-002 can be used in anxiety disorder and inflammation research[1] [2] [3].

OG-L002 is an effective and selective LSD1 inhibitor (IC50: 20 nM), showing 69- and 36-fold selectivity over MAO-A and MAO-B, respectively.

IST5-002 (N6-Benzyladenosine-5'-phosphate) is a selective Stat5a/b inhibitor with anticancer activity that inhibits the transcriptional activity of Stat5a/b and induces apoptosis and death of prostate cancer cells and chronic myelogenous leukemia (CML) cells, which can be used for cancer research.

(Rac)-ZLc-002 is a compound that inhibits the interaction between neuronal nitric oxide synthase (nNOS) and the nitric oxide synthase 1 adaptor protein (NOS1AP), effectively reducing inflammatory pain and chemotherapy-induced neuropathic discomfort. Additionally, it enhances the efficacy of Paclitaxel in decreasing tumor cell viability [1] [2].

ABX-002 (MA-JD21) is a TR-β selective, CNS-penetrant TR-β agonist prodrug, utilized for research on major depressive disorder (MDD) [1].

CVM-05-002 is a PI5P4K inhibitor that exhibits differential inhibitory potency against PI5P4Kα and PI5P4Kβ, with IC₅₀ values of 0.27 μM and 1.7 μM, respectively.

YH-002 is a human IgG1 monoclonal antibody (mAb) that specifically targets TNFRSF4/OX40/CD134. It binds to OX40 by mimicking the function of OX40L.

VLST-002 is a human antibody expressed in CHO cells, targeting CCL5/RANTES. It consists of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for VLST-002 is Human IgG1 kappa, Isotype Control.

IN-002 is a human monoclonal antibody targeting the F, FusionglycoproteinF0. It is used in the study of respiratory syncytial virus (RSV) infection.

RTX-002 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. This compound is applicable in the research of autoimmune diseases such as systemic lupus erythematosus and multiple sclerosis.

IDB-002 is a human monoclonal antibody (mAb) targeting the F/FusionglycoproteinF0. It is suitable for research related to respiratory syncytial virus infections. The recommended isotype control for this study is Human IgG1 kappa, Isotype Control.

VRDN-002 is a humanized monoclonal antibody (mAb) targeting IGF1R/CD221. It is designed to reduce inflammation and exophthalmos associated with thyroid eye disease (TED). Additionally, VPI-2690B is utilized in research related to Graves' ophthalmopathy.